Search

Displaying results 2331 - 2340 of 5089 in total
  1. Drug

    Lobeline

    go.drugbank.com/drugs/DB05137
    Investigational

    An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, a...

  2. Drug

    24-Homo-1,25-dihydroxyvitamin D3

    go.drugbank.com/drugs/DB15557
    Experimental

    24-Homo-1,25-dihydroxyvitamin D3 is a novel [vitamin D] analogue.

    Synonyms: 24-Homo-1,25-dihydroxyvitamin D3Categories: Vitamin D and Analogues
  3. Drug

    Theralizumab

    go.drugbank.com/drugs/DB15717
    Investigational

    After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia and human cytokine release).[A216527,A216532]

  4. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metab...

  5. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate ...

  6. Drug

    Gadoteridol

    go.drugbank.com/drugs/DB00597
    ApprovedInvestigational

    [A263076,A263081,L49871] It was 1 of the 3 macrocyclic gadolinium-based contrast agents (GBCAs) that was mandated by the EMA to replace linear gadolinium-based contrast agents due to concerns about retained

    Synonyms: GD-HP-DO 3A
  7. Drug

    Betahistine

    go.drugbank.com/drugs/DB06698
    ApprovedInvestigational

    [A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy.

  8. Drug

    Drometrizole trisiloxane

    go.drugbank.com/drugs/DB11585
    Approved

    The compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia

  9. Drug

    Trifarotene

    go.drugbank.com/drugs/DB12808
    ApprovedInvestigational

    [A187081] Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects

  10. Drug

    Betrixaban

    go.drugbank.com/drugs/DB12364
    Approved

    It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [A27286].